REPLIGEN DROPS HIV VACCINE PROGRAM AS PART OF STREAMLINING
Executive Summary
REPLIGEN DROPS HIV VACCINE PROGRAM AS PART OF STREAMLINING announced July 19. Repligen's RP400c therapeutic HIV vaccine targeting the V3 loop of the virus was in Phase I studies at the University of Colorado, and the company was also involved in research for a prophylactic vaccine. Both programs have been dropped because of "a lack of available funding and the exponentially increasing expenses associated with the clinical development of an HIV vaccine," Repligen said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth